Project Grant R43DA064271
Award Date 8/15/25
Completion Date 7/31/26
Dollars Obligated $404K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,715.00 to Rescue Biomedical, LLC to develop and commercialize the Automatic Detection Device (AD2) component of their Automatic Antidote Delivery Device (A2D2). The AD2 is a user-centric wearable device that aims to automatically detect opioid overdose and respiratory depression, with the goal of reducing the need for intensive...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $591,752 Project Grant to Oprems LLC to develop a digital platform for electronic screening to identify the risk of opioid misuse and overdose. The project aims to integrate the tools and processes from Oprems' existing paper-based "ONE (Opioid and Naloxone Education)" program into a tablet-based digital platform. This digital platform will be used to consistently...
- The National Science Foundation (NSF) awarded a Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Resilient Lifescience, Inc. for the development and validation of a novel wearable medical device to detect and treat opioid overdose. The $274,964 award, effective March 15, 2024 through December 31, 2024, will fund the development of two key components: 1) a self-contained, patch-based drug delivery platform capable of reliably delivering multiple...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a software-based medical device (SAMD) for detecting opioid use through voice analysis. The $800,000 award to Tenvos Inc., a minority-owned and woman-owned technology company, aims to advance the company's AI-driven solution that can enable patients to remotely test for opioid use and securely share results with...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $305,369 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Taesun, LLC in Colorado. The grant, with a period of performance from August 1, 2025 to January 31, 2026, is for the development of a comprehensive device that integrates fentanyl test strips with sample preparation features to enable convenient and discreet fentanyl testing in high-risk environments....
- This Project Grant, awarded by the National Institute on Drug Abuse (NIDA), will fund research to develop an advanced optical device that can quantify cerebral oxygenation and blood flow in infants with prenatal opioid exposure. The $251,006 award will support a 2-year study (7/15/2025 - 6/30/2027) to acquire longitudinal data on cerebral physiology in the first week of life for this population and evaluate associations with short-term clinical outcomes. The proposed hybrid device that...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $306,872 Project Grant to Biomotivate LLC to develop and evaluate the PEACE Platform, a novel solution that leverages personalized audiovisual content and machine learning algorithms to help individuals with opioid use disorders (OUDs) build their capacity to manage negative emotions and stressors. The research design involves integrating generative AI, predictive...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $386,452 to Electronic Biosciences, Inc. to develop rapid fingerstick diagnostics for opioid and stimulant use disorders. The award period is from April 1, 2025 to March 31, 2026. The project aims to address the escalating public health crisis of opioid and stimulant use disorders, which have contributed to over 107,000 overdose deaths in the...
- This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
- This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $399,536 to Chemregen Inc. for the project "IPSC-DERIVED HUMAN NEURONS AND OUD MEDICATIONS DEVELOPMENT". The project aims to design, synthesize, and test non-opioid drug candidates and validate a molecular target for combating the opioid crisis, with a focus on addressing the dangers of fentanyl. Key activities include chemically and...